EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

What CGT can learn from biologics: high‑value AI use cases for manufacturing

Shyam Panjwani

Cell and Gene Therapy Insights · 30.07.2026 · 12 (6) · 675–678

DOI: 10.18609/cgti.2026.080 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cell and Gene Therapy Insights, online erschienen am 30.07.2026. Verfasst von Shyam Panjwani. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cell and gene therapy manufacturing continues to face efficiency and scalability challenges, yet the sector can draw directly on the biopharmaceutical industry’s established experience applying AI and machine learning across biologics production, spanning digital infrastructure, process analytical technology (PAT), cloud-based digital applications, and generative AI. This article examines how those lessons translate to CGT, arguing that manufacturers should prioritize electronic batch records, contextualized metadata, and cloud-based data pipelines before layering on advanced AI, while planning early for GMP validation of AI-driven tools.

Zitieren

APA

Panjwani, S. (2026). What CGT can learn from biologics: high‑value AI use cases for manufacturing. Cell and Gene Therapy Insights, 12(6), 675–678. https://doi.org/10.18609/cgti.2026.080

Vancouver

Panjwani S. What CGT can learn from biologics: high‑value AI use cases for manufacturing. Cell and Gene Therapy Insights. 2026;12(6):675–678. doi:10.18609/cgti.2026.080

BibTeX
@article{Panjwani2026,
  author = {Panjwani, Shyam},
  title = {What CGT can learn from biologics: high‑value AI use cases for manufacturing},
  journal = {Cell and Gene Therapy Insights},
  year = {2026},
  volume = {12},
  number = {6},
  pages = {675–678},
  doi = {10.18609/cgti.2026.080}
}
Kostenlos starten →